e-ISSN 1309-2545      ISSN 1301-062X

Download Current Issue.

Volume : 28 Issue : 2 Year : 2022

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login Copyright Transfer Form
Turkish Journal of Neurology Indexed By
  Mitoxantrone in the treatment of multiple sclerosis: a single-center experience [Turk J Neurol]
Turk J Neurol. 2012; 18(2): 62-66 | DOI: 10.4274/Tnd.38039  

Mitoxantrone in the treatment of multiple sclerosis: a single-center experience

Özlem Taşkapılıoğlu1, Deniz Kamacı Şener1, Aslı Bahar Turan1, Şükran Yurtoğulları1, Ahmet Tütüncü2, Sümeyye Güllülü2, Gökhan Ocakoğlu3, Ömer Faruk Turan1
1Uludag University Medical Faculty, Neurology Department, Bursa
2Uludag University Medical Faculty, Cardiology Department, Bursa
3Uludag University Medical Faculty, Biostatistics Department, Bursa

OBJECTIVE: To investigate the secondary progressive multiple sclerosis (SPMS) patients treated with mitoxantrone (MIT) and discuss the effectiveness and side effects of MIT.
METHODS: We retrospectively investigated 48 SPMS patients who completed or were still receiving MIT treatment. Expanded Disability Status Scale (EDSS) scores of the patients were determined who had detailed examination before the treatment. Complete blood count, urine examination, chest x-ray, kidney and liver function tests, transthoracic echocardiography were performed at initiation and during follow-up and 10 mg/m2 MIT was administered every three months. The data were assessed in order to determine the effectiveness and side effects.
RESULTS: A total of 48 patients, 34 women and 14 men, had an age of 42 (26-55) years at the initiation of MIT treatment. The duration of the treatment was 12 (3-30) months. The median EDSS scores were 6 (4-8) before the treatment and 6 (4-9) after the treatment. EDSS scores improved in 6 patients, deteriorated in 12 patients and 30 patients remained with stable EDSS scores during the treatment. Seventeen patients had no side effects however 31 patients developed side effects.
CONCLUSION: On the basis of this study, which is a clinical assessment of the effectiveness and side effects of MIT, we conclude that MIT can limit disability in SPMS patients and it is useful in treating SPMS patients due to favorable risk-benefit ratio.

Keywords: Multiple sclerosis, secondary progressive multiple sclerosis, immunosuppressive agents, immunomodulators, mitoxantrone

Özlem Taşkapılıoğlu, Deniz Kamacı Şener, Aslı Bahar Turan, Şükran Yurtoğulları, Ahmet Tütüncü, Sümeyye Güllülü, Gökhan Ocakoğlu, Ömer Faruk Turan. Mitoxantrone in the treatment of multiple sclerosis: a single-center experience. Turk J Neurol. 2012; 18(2): 62-66

Corresponding Author: Deniz Kamacı Şener, Türkiye

Full Text PDF
Download citation
Reference Manager
Share with email
Send email to author

Similar articles
Google Scholar

© Copyright 2022 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale